Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma is a phase 2, interventional study registered as NCT06831136 by The University of Texas Health Science Center, Houston, with a registry enrolment figure of 24 participants, started 2025-03-26 and due to reach its primary completion in 2028-01-20. Interventions recorded: Neoadjuvant Chemotherapy (NAC); Immunotherapy (pembrolizumab); Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA). Conditions listed: Pancreatic Ductal Adenocarcinoma. Primary outcome: Efficacy as assessed by the Overall response rate using RECIST v1.1 guidelines. Pancreatic eligibility wording from the registry: "Patients who have undergone prior resection will be excluded unless there is recurrent pancreatic tumor that is amenable to EUS-RFA". Sites: United States. No results are recorded here; the registry entry is the source.